CN114668788A - Application of blumea oil inclusion compound in preparation of medical spray for treating asthma - Google Patents
Application of blumea oil inclusion compound in preparation of medical spray for treating asthma Download PDFInfo
- Publication number
- CN114668788A CN114668788A CN202210537995.XA CN202210537995A CN114668788A CN 114668788 A CN114668788 A CN 114668788A CN 202210537995 A CN202210537995 A CN 202210537995A CN 114668788 A CN114668788 A CN 114668788A
- Authority
- CN
- China
- Prior art keywords
- inclusion compound
- mice
- treating asthma
- medical spray
- folium artemisiae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicine preparations, and particularly relates to application of an oleum folium artemisiae argyi inclusion compound in preparation of a medical spray for treating asthma. The invention provides a new application of folium artemisiae argyi volatile oil serving as an effective component in preparing a medical spray for treating asthma. The application amount of the blumea oil inclusion compound in mice is atomized according to 13.89mg/kg and 6.96mg/kg body mass, and the level of inflammatory cytokines in mice BALF and OVA-sIgE in mice serum can be reduced after administration. Reduce the total number of white blood cells in BALF (bronchoalveolar lavage fluid) of mice, and inhibit infiltration of inflammatory cells of lung tissues and secretion of airway mucus. Has the advantages of simple preparation process, low toxic and side effects, nature, safety and the like. The invention develops new application of the blumea oil and provides a new direction for improving the phenomena of more adverse reactions and large toxic and side effects of the existing asthma treatment medicines.
Description
Technical Field
The invention relates to the technical field of medical treatment, belongs to the field of traditional Chinese medicine preparations, and particularly relates to application of a blumea oil inclusion compound in preparation of a medical spray for treating asthma.
Background
Bronchial asthma (bronchial asthma), abbreviated as asthma, is a chronic inflammatory lung disease. In recent years, the prevalence rate of asthma is increasing worldwide, which poses a great threat to human health and is one of the global health problems that are receiving human attention today. (Zhao Wen Juan, Han Ni Ping, Chenjing, et al. Experimental study of crude Notoginseng powder for regulating airway inflammation and Th subgroup-associated cytokines in asthmatic mice [ J ].2014,9(12): 4). Asthma is a complex inflammatory disease characterized by airway hyperresponsiveness, airway inflammation and goblet cell mucus hypersecretion, with inflammatory mediators such as IL-4, IL-5 and IL-13 produced by cells in the lung, resulting in the development of an airway inflammatory response. It is now generally accepted that the Th-centered immune response of T cells in particular is closely associated with the development of asthma airway inflammation. Among them, T helper type 2 cells (Th 2) are abundantly present in the airways, and secreted Th2 factors such as interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-13 (IL-13) play a key role in the pathophysiology of asthma (K.Xue, L.Ruan, J.Hu, et al.Panax notogeng saponin R1 models TNF- α/NF- κ B signaling and apoptosis allogenic air intake in asthma [ J ] 2020,88: 106860). IL-4 can stimulate Th0 cells to differentiate into Th2 cells, promote B lymphocytes to proliferate, induce the B lymphocytes to differentiate into plasma cells, and synthesize IgE; IL-5 is a cytokine that has a significant regulatory effect on the growth, maturation, and activation of eosinophils; the IL-13 signal pathway is an important relevant pathway for mucus secretion, and can promote goblet cell proliferation, induce large amount of mucus protein secretion and increase airway reactivity.
At present, the clinically commonly used drugs for treating asthma, such as glucocorticoid, leukotriene receptor blocker, beta 2 adrenoceptor agonist and the like, can rapidly control airway inflammation, and have good effect, but still have some disadvantages, such as relapse after drug withdrawal, systemic or local adverse reaction caused by long-term drug administration, hypokalemia caused by electrolyte disorder and the like (plum is thick and faithful, high-shinning Yu, Huangwei, et al. the influence of traditional Chinese medicine bulbus fritillariae cirrhosae on MMP-2, MMP-9 and TIMP-1 of asthma model mice [ J ].2017,42(21): 7). Compared with the traditional administration modes such as oral administration or intravenous injection, the aerosol inhalation therapy can directly deliver the medicine to the lung so as to directly act on the lung, thereby having faster effect and better curative effect; and the required dosage is less, the absorption into blood is less, and the adverse reaction of the whole body is rarely caused, so the toxic and side effect is less. In addition, no solution-type spray for treating asthma is available on the market in China, and products on the market at home and abroad are all suspensions. After the suspension spray is shaken, the medicine is unevenly distributed, and after the suspension spray is used, the local medicine concentration is too high, which can stimulate the bronchus and is not beneficial to the absorption of the medicine. Modern clinical treatment has no specific radical cure method for asthma, but with the continuous development of medical science, the understanding of the pathogenesis, rule and treatment of asthma is greatly improved, and the number of effective new drugs and treatment measures is also infinite. The traditional Chinese medicine has unique advantages in the aspect of asthma treatment, has a good long-term curative effect in treating asthma, can be used for treating asthma according to a syndrome, and has the outstanding characteristics of treating both symptoms and root causes, small side effects and the like, so that the traditional Chinese medicine gradually becomes a new focus for people to explore asthma treatment.
The folium artemisiae argyi belongs to the dry leaves of the plant Artemisia argyi Levl. et Vant. of the Compositae, is a genuine medicinal material of Henan, and is produced in Henan Yang. Also is a folk-custom traditional Chinese medicine with long history and wide application in China, and has the functions of easing pain, resisting inflammation, relieving asthma and eliminating phlegm (the chemical component analysis of the artemisia leaf volatile oil prepared by three different extraction methods of showy red, Weidong and et al [ J ].2008,3(4): 5). The folium artemisiae argyi is rich in various bioactive components, wherein volatile oil is a main active component group of the folium artemisiae argyi. The study shows that the folium artemisiae argyi has obvious anti-inflammatory and antiasthmatic activities, and the anti-inflammatory and antiasthmatic activities are mainly from volatile oil components of the folium artemisiae argyi. (Zhengkun, Shifei, Zhangzhou province of Experimental and prescriptions J. the research progress of volatile oil components of mugwort leaves and their pharmacological actions [ J ].2020,26(18): 11). The application of the volatile oil of the artemisia argyi is seriously influenced due to the strong volatility, the irritation, the instability of light and heat, the poor water solubility and the like of the volatile oil of the artemisia argyi, and the defects of the volatile oil of the artemisia argyi can be overcome and compensated by a cyclodextrin inclusion technology. After the cyclodextrin inclusion compound is prepared into the cyclodextrin inclusion compound, the physicochemical properties of the cyclodextrin inclusion compound can be obviously improved, such as the stability of the medicament is improved, the solubility and the bioavailability of the insoluble medicament are increased, the toxic and side effects of the medicament are reduced, the unpleasant odor is covered, and the like. At present, the application of folium artemisiae argyi volatile oil as a drug effect component or the application of folium artemisiae argyi volatile oil inclusion compound to prepare a medical spray for preventing and/or treating asthma is not reported.
Disclosure of Invention
Based on the accidental discovery of the inventor, the invention provides a new application of folium artemisiae argyi volatile oil serving as a main effective component in preparing a medical spray for treating asthma.
In order to realize the purpose, the invention provides the following technical scheme:
preparing the blumea oil inclusion compound: adopting a saturated aqueous solution method, selecting hydroxypropyl-beta-cyclodextrin (HP-beta-CD) as an inclusion material, wherein the weight ratio of the folium artemisiae argyi volatile oil to the HP-beta-CD is (2-5): 1, mixing and reacting to obtain the blumea oil inclusion compound.
The obtained oleum folium Artemisiae Argyi clathrate is used as active ingredient to prepare medical spray for treating asthma.
Female BALB/C mice are taken as study objects, an ovalbumin and aluminum hydroxide are used for inducing a mouse asthma model, and traditional Chinese medicine extract folium artemisiae argyi volatile oil is prepared into an inclusion compound for atomization administration for intervention, so that the drug effect of the folium artemisiae argyi oil inclusion compound in preparing a medical spray for treating asthma is verified. The application amount of the oleum folium Artemisiae Argyi clathrate in mice is 13.89mg/kg and 6.96mg/kg body weight by atomizing administration.
The specific scheme is as follows: intraperitoneal injection of 0.2mL of sensitizing solution (containing 50 ug of OVA and 2mg of aluminum hydroxide) is carried out on days 0, 7 and 14 for sensitization, and 2% OVA atomization is adopted on days 21-27 for inducing the asthma model of mice (Liyunxing, chime, Wangyong, Magua China journal of Compare medicine. establishment of common asthma animal model [ J ].2020,30(11): 5). 30min before each excitation, the blumea oil inclusion compound aqueous solution prepared by the invention is used for treatment in an atomization administration mode. The results show that: compared with a blank control group, the level of OVA-sIgE in the blood serum of mice in the asthma model group and the total number of IL-4, IL-5, IL-13 and WBC in BALF are obviously increased. Compared with a model control group, the levels of OVA-sIgE in the serum of mice in the blumea oil clathrate compound atomization administration group are obviously reduced, the contents of IL-4, IL-5 and IL-13 in BALF are restored to normal levels, and the total number of white blood cells in BALF sediment is obviously reduced. The HE staining result shows that the normal mice have complete alveolar walls and thin walls in peripheral lung tissues and hardly have inflammatory cell infiltration when subjected to HE staining. The model group rat alveolar wall is thickened, partial area wall is broken, and a large amount of inflammatory cells infiltrate. The mice in the blumea oil inclusion compound group still have more inflammatory cell infiltration and alveolar wall thickening, but the pathological changes are obviously improved compared with the mice in the model group. PAS staining results show that the goblet cells of the mice in the normal group are proliferated and mucus is secreted less; a large amount of inflammatory cells infiltrate under the mucosa of the model group, and goblet cell hyperplasia and mucus secretion are obviously visible; compared with the model group, the blumea oil inclusion compound group has obviously reduced inflammatory cell infiltration, goblet cell hyperplasia and mucus secretion under the mucous membrane. Therefore, the blumea oil inclusion compound has obvious anti-inflammatory effect, the capacity of regulating imbalance of Th1/Th2 and inhibiting mucus secretion, has certain prevention and treatment effect on asthma diseases, and can be used for preparing a medical spray for treating asthma.
The medical spray for treating asthma contains the folium artemisiae argyi oil inclusion compound, can be a medicine only containing the folium artemisiae argyi oil inclusion compound, and can also be a medicine composition containing the folium artemisiae argyi oil inclusion compound. The pharmaceutical composition containing the blumea oil inclusion compound comprises the blumea oil inclusion compound and a pharmaceutical ingredient which has a positive effect on treating asthma and/or a pharmaceutically acceptable ingredient and/or a pharmaceutically acceptable auxiliary ingredient for improving the stability of the blumea oil inclusion compound after being simultaneously administered with the blumea oil inclusion compound.
The medical spray for treating asthma provided by the invention is in a form of solution. During the use, directly spout into the throat, the medicine is inhaled through the atomizing and is directly acted on the pathological change position, compares with other traditional modes of dosing such as oral administration and has the following advantage: 1. the effect is quick: in the atomization process, the liquid medicine is processed into mist and enters a human body through the respiratory tract of a patient, and the medicine inhaled in the mode can directly reach the focus of the respiratory tract and the lung, so that the medicine is more targeted, takes effect more quickly and has better effect compared with oral medicines. 2. Reducing the side effects of the drug: the aerosol inhalation belongs to the respiratory tract local medication, has smaller dosage than oral administration or transfusion medication, and is beneficial to reducing the toxic and side effects of the medicine. 3. The effect is good: through atomization administration, the medicine can directly humidify the air passage, dilute the sputum, facilitate the discharge of the sputum and be beneficial to the treatment of respiratory diseases such as cough, bronchitis and the like. 4. The existing atomization treatment device is simple and easy to learn in operation and is easy to accept by patients; and the aerosol inhalation therapy does not need the patients to be matched with each other intentionally, so the aerosol inhalation therapy is suitable for most patients, especially children, old people and patients with disturbance of consciousness. 5. The aerosol inhalation has high safety and is suitable for children of all ages.
Compared with the prior art, the invention has the beneficial effects that:
the invention uses the blumea oil inclusion compound to prepare the medical spray for treating asthma, which can reduce the level of OVA-sIgE in the serum of mice, reduce the content of IL-4, IL-5 and IL-13 and the total WBC number in BALF of the mice, has obvious effect of treating asthma, and has the advantages of small dosage, low toxic and side effect, small irritation to bronchus and the like. Develops a new application of the folium artemisiae argyi volatile oil, and provides a new direction for improving the phenomena of more adverse reactions and large toxic and side effects of the existing asthma treatment medicines. In addition, the medicine is prepared into a spray which is convenient to take and carry and has quick drug effect, and the asthma in bronchial asthma attack can be quickly and effectively relieved.
Drawings
FIG. 1 is a schematic diagram of the effect of the inclusion compound of Artemisia princeps oil of the invention on the reduction of mouse serum OVA-sIgE level.
FIG. 2 is a schematic diagram showing the effect of the blumea oil inclusion compound on the reduction of the total number of leukocytes in mouse BALF sediment.
FIG. 3 is a schematic diagram of the change of IL-4, IL-5 and IL-13 levels in mouse BALF by using the blumea oil clathrate compound. Wherein, the graph A is a statistical graph of the level of interleukin-4 (IL-4) in mouse BALF; panel B is a statistical plot of the interleukin-5 (IL-5) levels in mouse BALF; panel C is a statistical plot of the interleukin-13 (IL-13) levels in mouse BALF.
FIG. 4 is a schematic diagram of the observation of lung tissue inflammatory cell infiltration by HE staining (x400) of mice in each group.
FIG. 5 is a diagram showing the observation of lung goblet cell proliferation and mucus secretion by PAS staining (x400) of mice in each group.
Note: # indicates P < 0.001 compared to group C; # indicates P < 0.01 compared to group C; # denotes P < 0.05 compared to group C;
p < 0.001 compared to group M; p < 0.01 compared to group M; denotes P < 0.05 compared to group C.
Detailed Description
The present invention will be described in further detail with reference to specific embodiments for better illustrating the objects, technical solutions and advantages of the present invention, but the present invention is not limited to the following examples.
In the following embodiments, the biochemical reagents not specifically described are all conventional reagents in the art, and can be prepared according to conventional methods in the art or obtained commercially, and the specification is laboratory pure grade, and the percentages are all mass percentages unless specifically described.
Test method
The medicinal source is folium Artemisiae Argyi volatile oil from Henan south Yang Lanhaisen source medicine science and technology company, Henan south Yang Lanhaisen; the drug budesonide suspension was purchased from Zhengda Nissin pharmaceutical industry group with specification 2 mL: 1 mg; the inclusion material HP-beta-CD was purchased from Zibo Qiaohi Biotech, Inc.; ovalbumin OVA was purchased from Beijing Solaibao science and technology, Inc.; aluminum hydroxide was purchased from Beijing Sorbao technologies, Inc. at a purity of > 75%.
The preparation method comprises preparing folium Artemisiae Argyi oil clathrate into water solution with physiological saline; the budesonide suspension (positive protectant) is diluted with physiological saline; the sensitizing solution is prepared from ovalbumin and aluminum hydroxide by using normal saline (each 0.2mL of sensitizing solution contains 50 μ g of OVA and 2mg of aluminum hydroxide); the exciting liquid is prepared by dissolving 70mgOVA in 35mL of normal saline to prepare 2% OVA exciting liquid.
Animal breeding, 60 healthy female BALB/C mice with the weight of 18-22g are provided by animal experiment centers in Henan province, and the license number is SCXK (Yu) 2017-. The breeding environment is of SPF level, independent air intake and return purification Cages (IVC) are arranged, the temperature is constant (22 +/-2 ℃), the humidity is constant (55% soil 15%), the light and shade alternate every 12 hours, one cage is arranged for every 12 mice, autoclaved water is drunk, and the mice can eat freely.
The administration mode is characterized in that the ovalbumin and aluminum hydroxide sensitizing solution adopts an intraperitoneal injection administration mode, and the blumea oil inclusion compound, the budesonide suspension and the normal saline all adopt an atomization administration mode.
Example 1
The invention relates to the influence of the inclusion compound of the blumea oil on OVA and aluminum hydroxide induced mouse asthma.
60 healthy female BALB/C mice, 18-22g in weight, were provided by the animal testing center in Henan province. The mice are adaptively bred in SPF (specific pathogen free) animal rooms of Zhengzhou university college of medicine of Henan province for one week, and are divided into 5 groups by a random digital table method, wherein each group comprises 12 mice, and the method comprises the following steps:
1. a normal control group; (C)
2. a model control group; (M)
3. A positive control group; (B)
4. the folium Artemisiae Argyi oil inclusion compound high dose group. (AH)
5. The low dose group of the blumea oil inclusion compound. (AM)
After the end of the acclimation period, molding + administration was started. Firstly, a model control group, an artemisia oil inclusion compound group and a positive control group are administered on days 0, 7 and 14 to be sensitized in an OVA combined aluminum hydroxide intraperitoneal injection (10mL/kg), and a normal control group is administered with an equal amount of normal saline intraperitoneal injection; on days 21-27, normal control group is atomized and excited with normal saline, other groups are atomized and excited with 2% OVA, administration is performed 30min before each excitation, normal control group and model control group are administered with normal saline for atomization and administration for 30min, folium Artemisiae Argyi oil clathrate group is administered with folium Artemisiae Argyi oil clathrate aqueous solution for atomization and administration for 30min, and positive control group is administered with budesonide suspension for atomization and administration for 30 min. The mice were weighed and recorded daily for 7 consecutive days.
After 24 hours from the end of the last dose, an eye was removed. Standing the obtained blood at room temperature for 3h, centrifuging at 3500r/min for 10min, taking the supernatant in a freezing tube, immediately putting into liquid nitrogen, and storing at-80 ℃ for subsequent experiments. The mouse is killed by intraperitoneal injection of an excessive anesthetic, the mouse is fixed on an anatomical plate, the abdomen and the chest of the mouse are opened, the skin and the redundant tissues of the neck are cut off, the trachea of the mouse is exposed, the left lung of the mouse is ligated by an operation line, a small opening is cut on the transverse axis of the trachea by a small scissors, the lmL syringe needle which is pretreated before extraction is inserted, and the needle is fixed by the operation line. 0.4mL of pre-cooled Phosphate Buffer (PBS) was drawn in with a 1mL syringe and slowly injected into the mouse lungs, followed by slow aspiration. And 3 times of lavaging of each mouse, wherein the recovery rate of more than 80 percent is a qualified sample (Guo Yao. dendrobium officinale compound preparation has influence on the immune function of C57BL/6 asthmatic mice [ J ]). After the mouse alveolar lavage is finished, the left ligated lung is taken out, the blood is washed by normal saline, and the left ligated lung is fixed in 10% paraformaldehyde after being washed clean for subsequent tissue section. The remaining lung was excised, placed in a cryovial, immediately placed in liquid nitrogen and stored at-80 ℃ for subsequent experiments. Centrifuging alveolar lavage fluid at 4 deg.C, 7500rpm for 5min, packaging supernatant, and storing at-80 deg.C. The cell pellet was resuspended in 0.5mL of pre-cooled PBS and an equal amount of white blood cell counting solution was added and the total white blood cells were counted on a blood cell counting plate.
Counting the white blood cells in the BALF sediment by using a white blood cell counting solution; the levels of OVA-sIgE in mouse serum and IL-4, IL-5 and IL-13 in BALF were determined by ELISA kit, and the specific procedures were performed according to the kit instructions.
The statistical analysis method comprises the following steps:
the results are expressed as means ± SE and the comparison of the mean of the two samples is performed by t-test.
One week after the aerosol challenge, the mice showed marked symptoms of increased respiration, nodding respiration, marked abdominal respiration, quiet and restlessness or restlessness, unstable standing, ear grasping, sneezing, incontinence of urine and feces, and the mice were not responsive enough, had dark hair color, decreased water intake, and showed successful modeling (tuohai, wang, anyuan, et al, ovalbumin replicated asthma animal models and evaluation research progress [ J ] 2016 (1): 4). The normal control mice showed normal performance.
The results are shown in figure 1, compared with the normal control group, the content of OVA-sIgE in the serum of the mice in the model control group is obviously increased, which indicates that the modeling is successful.
The result is shown in fig. 2, the total number of leukocytes in BALF of mice in the blumea oil inclusion compound group is significantly reduced compared with that of the model control group, which indicates that the blumea oil inclusion compound has good anti-inflammatory ability.
The results are shown in figure 3, and the levels of IL-4, IL-5 and IL-13 in mouse BALF supernatant in the blumea oil clathrate group are obviously reduced and almost recovered to normal levels compared with the model control group, which indicates that the blumea oil clathrate compound has good capability of regulating TH1/TH2 imbalance.
The results are shown in fig. 4, and the HE staining results show that the infiltration of inflammatory cells in lung tissues and the shedding of bronchial epithelial cells of mice in the blumea oil clathrate group are obviously reduced compared with the model control group.
The results are shown in fig. 5, and PAS staining results show that submucosal inflammatory cell infiltration, goblet cell proliferation and mucus secretion of mice in the blumea oil inclusion compound group are obviously reduced.
Claims (3)
1. The application of the blumea oil inclusion compound in preparing the medical spray for treating asthma is characterized in that the blumea oil inclusion compound is used as an active ingredient and is prepared into the medical spray for treating asthma; the blumea oil inclusion compound is prepared by the following method: adopting a saturated aqueous solution method, selecting hydroxypropyl-beta-cyclodextrin as an inclusion material, wherein the weight ratio of the hydroxypropyl-beta-cyclodextrin to the folium artemisiae argyi volatile oil is 2-5: 1, mixing and reacting to obtain the blumea oil inclusion compound.
2. The use of the oleum folium artemisiae argyi inclusion compound in the preparation of a medical spray for treating asthma according to claim 1, wherein the medical spray comprises pharmaceutically acceptable auxiliary components.
3. The use of the oleum folium Artemisiae Argyi clathrate compound according to claim 1 or 2, in the preparation of medical spray for treating asthma, characterized in that the dosage form of the medical spray medicine is selected from solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210537995.XA CN114668788A (en) | 2022-05-17 | 2022-05-17 | Application of blumea oil inclusion compound in preparation of medical spray for treating asthma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210537995.XA CN114668788A (en) | 2022-05-17 | 2022-05-17 | Application of blumea oil inclusion compound in preparation of medical spray for treating asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114668788A true CN114668788A (en) | 2022-06-28 |
Family
ID=82079601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210537995.XA Pending CN114668788A (en) | 2022-05-17 | 2022-05-17 | Application of blumea oil inclusion compound in preparation of medical spray for treating asthma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114668788A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115944662A (en) * | 2022-12-23 | 2023-04-11 | 中南民族大学 | Application of folium artemisiae argyi volatile oil serving as TRPA1 pathway inhibitor in anti-inflammatory and antipruritic medicines |
-
2022
- 2022-05-17 CN CN202210537995.XA patent/CN114668788A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 周瑶等: "艾叶挥发油-环糊精包合物研究概述", 食品工业, vol. 41, no. 8, pages 240 - 244 * |
| 张志等: "艾叶挥发油-羟丙基-β-环糊精包合物的制备及鉴定", 时珍国医国药, vol. 29, no. 6, pages 1356 - 1357 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115944662A (en) * | 2022-12-23 | 2023-04-11 | 中南民族大学 | Application of folium artemisiae argyi volatile oil serving as TRPA1 pathway inhibitor in anti-inflammatory and antipruritic medicines |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109999052B (en) | Use of beta-nicotinamide mononucleotide or a precursor thereof for the manufacture of a medicament for the treatment or alleviation of a respiratory disorder or disease | |
| CN114668788A (en) | Application of blumea oil inclusion compound in preparation of medical spray for treating asthma | |
| CN103272083B (en) | Pharmaceutical composition for preventing and/or treating asthma, its preparation method and application | |
| CN108498743B (en) | Traditional Chinese medicine formula for treating lung-qi deficiency syndrome of chronic obstructive pulmonary disease | |
| WO2016019736A1 (en) | Schisandra extract for treating coughs and alleviating airway inflammations, and preparation method and use thereof | |
| WO2024011800A1 (en) | Traditional chinese medicine composition for treating cough variant asthma and preparation method therefor | |
| CN109106774B (en) | Traditional Chinese medicine composition for treating adenoidal hypertrophy and complications thereof, and preparation method and application thereof | |
| CN111714580A (en) | Application of radix scutellariae cough-relieving medicine in preparing medicine for resisting allergic asthma | |
| CN1660256A (en) | Medication for treating cough caused by inflammation of upper respiratory tract | |
| CN117298124B (en) | Application of ganoderic acid T in preparation of medicine for treating allergic asthma | |
| CN117224518B (en) | Application of sofalcone in preparation of medicine for preventing/treating allergic asthma | |
| CN115721689B (en) | Application of tortoise-deer kidney-tonifying pill in preparation of medicine for preventing and treating bronchial diseases | |
| CN114470110B (en) | Anti-rhinitis traditional Chinese medicine composition with pain relieving effect | |
| CN115068549B (en) | Atomized product for treating acute bronchitis cough of children and preparation method thereof | |
| WO2008095429A1 (en) | A glycoprotein for treating chronic obstructive pulmonary diseases | |
| CN109394776B (en) | Traditional Chinese medicine component formula for treating diffuse interstitial pulmonary fibrosis and application thereof | |
| CN116211950B (en) | Hosta plantaginea flower traditional Chinese medicine composition for treating rhinitis | |
| CN114392322B (en) | Traditional Chinese medicine granule and preparation method and application thereof | |
| CN110051778B (en) | Sore throat relieving tea for treating chronic pharyngitis and preparation method thereof | |
| CN111419883B (en) | Preparation method of nasal spray for treating allergic rhinitis | |
| CN101797258A (en) | Medicine composition containing oral glucocorticoid and oral bronchodilator | |
| KR102410183B1 (en) | Preparation for inhalation of isoglycyrrhizic acid or a salt thereof, and use in the manufacture of a medicament for treating diseases of the respiratory tract | |
| CN114588134A (en) | Traditional Chinese medicine composition atomized liquid for preventing and assisting in treating respiratory diseases and application | |
| Wei et al. | Effect of kekeling mixture on the levels of IL-6 and IL-8 in RSV infected mice. | |
| CN117159661A (en) | Traditional Chinese medicine composition, preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |